Trial Profile
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2017
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- 17 Sep 2015 As per NCT Primary end point was changed from "prevention of new brain metastases" to "Percentage of Participants With Distant Brain Failure (DBF) at One Year"
- 17 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrial.gov record..